"","Cites","Authors","Title","Year","Source","Publisher","ArticleURL","CitesURL","GSRank","QueryDate","Type","DOI","ISSN","CitationURL","Volume","Issue","StartPage","EndPage","ECC","CitesPerYear","CitesPerAuthor","AuthorCount","Age","Abstract","generic_drug_name"
"1",0,"M.S. Keszler","Rehabilitation of Individuals with Limb Loss due to Trauma",2020,"Current Trauma Reports",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085327088&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85085327088&origin=inward",6,"2021-01-16 11:59:06","Review","10.1007/s40719-020-00193-8","2198-6096","https://api.elsevier.com/content/abstract/scopus_id/85085327088",6,2,96,104,0,0,0,1,1,NA,"celecoxib"
"2",8,"K. Potter-Baker","Reliability of TMS metrics in patients with chronic incomplete spinal cord injury",2016,"Spinal Cord",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84962090359&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84962090359&origin=inward",5,"2021-01-16 11:59:06","Article","10.1038/sc.2016.47","1362-4393","https://api.elsevier.com/content/abstract/scopus_id/84962090359",54,11,980,990,8,1.6,8,1,5,NA,"celecoxib"
"3",10,"X. Hou","Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone",2015,"Neural Regeneration Research",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84949462316&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84949462316&origin=inward",4,"2021-01-16 11:59:06","Article","10.4103/1673-5374.170314","1673-5374","https://api.elsevier.com/content/abstract/scopus_id/84949462316",10,11,1836,1840,10,1.67,10,1,6,NA,"celecoxib"
"4",15,"A. Shao","Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation",2019,"EBioMedicine",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067211347&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85067211347&origin=inward",3,"2021-01-16 11:59:06","Review","10.1016/j.ebiom.2019.06.012","2352-3964","https://api.elsevier.com/content/abstract/scopus_id/85067211347",45,NA,615,623,15,7.5,15,1,2,NA,"celecoxib"
"5",40,"R. Masgrau","Should We Stop Saying ‘Glia’ and ‘Neuroinflammation’?",2017,"Trends in Molecular Medicine",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019033155&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85019033155&origin=inward",2,"2021-01-16 11:59:06","Review","10.1016/j.molmed.2017.04.005","1471-4914","https://api.elsevier.com/content/abstract/scopus_id/85019033155",23,6,486,500,40,10,40,1,4,NA,"celecoxib"
"6",320,"E. Hall","Neuroprotection and Acute Spinal Cord Injury: A Reappraisal",2004,"NeuroRx",NA,"https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=17444392322&origin=inward","https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=17444392322&origin=inward",1,"2021-01-16 11:59:06","Article","10.1602/neurorx.1.1.80","1545-5343","https://api.elsevier.com/content/abstract/scopus_id/17444392322",1,1,80,100,320,18.82,320,1,17,NA,"celecoxib"
